ALIM Key Stats
- Alimera Sciences (ALIM) Files 6.25M Common Shelf Street Insider 03/07 06:35 ET
- Alimera Sciences (ALIM) Target Raised to $7 at Northland Capital Markets Street Insider 03/03 08:13 ET
- Alimera Sciences To Present At Cowen And Company 34th Annual Healthcare Conference PR Newswire 02/28 07:30 ET
- Alimera Sciences Management Discusses Q4 2013 Results - Earnings Call Transcript Yahoo 02/27 18:30 ET
- Alimera Sciences Reports Fourth Quarter And Full Year 2013 Financial Results noodls 02/27 16:52 ET
- Alimera Sciences, Inc. Discusses Q4 2013 Results (Webcast) Seeking Alpha 02/27 16:25 ET
- ALIMERA SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi Yahoo 02/27 16:24 ET
- Alimera Sciences, Inc. (ALIM) Posts Q4 Loss of 24c/Share Street Insider 02/27 16:12 ET
- Alimera Sciences To Release Fourth Quarter And Fiscal Year 2013 Financial Results PR Newswire 02/20 16:05 ET
- Strength Seen in Retrophin (RTRX): Stock Soars 49.8% - Tale of the Tape Zacks 02/14 03:04 ET
ALIM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Alimera Sciences is up 118.2% over the last year vs S&P 500 Total Return up 24.45%, pSivida up 89.73%, and Affymetrix up 77.87%.
Balance Sheet View Statement
Pro Ratings for ALIM
Pro Strategies Featuring ALIM
Did Alimera Sciences make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Drug Manufacturers - Major
- Headquarters Country: United States
- Headquarters State/Province: Georgia
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Alimera Sciences, Inc., is a biopharmaceutical company engaged in the research, development, and commercialization of ophthalmic pharmaceuticals.